Gencellmed Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Series B
  • (Cancelled)

  • Investors
  • 9

Gencellmed General Information

Description

Developer of an anti-cancer drug treatment platform intended to develop next-generation immune-enhancing anti-cancer herpes virus (oHSV-1) drugs. The company specializes in developing the next-generation new drug against herpesviruses (oHSV-1) with dual action to stimulate the infectious power of cancer cells and the body's immune response, providing medical professionals with drugs to cure cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 302, Research Building Number 3, 75 Nowon-ro
  • Gongneung-dong, Korea Institute of Radiology, Nowon-gu
  • Seoul, 01812
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Room 302, Research Building Number 3, 75 Nowon-ro
  • Gongneung-dong, Korea Institute of Radiology, Nowon-gu
  • Seoul, 01812
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gencellmed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 24-Jul-2025 Cancelled Pre-Clinical Trials
4. Later Stage VC 16-Jul-2025 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 01-Apr-2021 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Oct-2019 Completed Pre-Clinical Trials
1. Seed Round 30-Sep-2019 Completed Pre-Clinical Trials
To view Gencellmed’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Gencellmed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an anti-cancer drug treatment platform intended to develop next-generation immune-enhancing anti-cancer her
Drug Discovery
Seoul, South Korea
9 As of 2025

Thousand Oaks, CA
 

Tokyo, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gencellmed Competitors (2)

One of Gencellmed’s 2 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA
Daiichi Sankyo Corporation Tokyo, Japan
You’re viewing 2 of 2 competitors. Get the full list »

Gencellmed Patents

Gencellmed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021287536-A1 Multi-targeting recombinant herpes simplex viruses and use thereof Active 12-Jun-2020
AU-2021287536-B2 Multi-targeting recombinant herpes simplex viruses and use thereof Active 12-Jun-2020
CA-3181143-A1 Multi-targeting recombinant herpes simplex viruses and use thereof Pending 12-Jun-2020
EP-4166656-A1 Multi-targeting recombinant herpes simplex viruses and use thereof Pending 12-Jun-2020
EP-4166656-A4 Multi-targeting recombinant herpes simplex viruses and use thereof Pending 12-Jun-2020 A61K35/763
To view Gencellmed’s complete patent history, request access »

Gencellmed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gencellmed Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Korean Venture Capital Association Venture Capital Minority
DAYLI Partners Venture Capital Minority
Innopolis Partners Venture Capital Minority
KDB Capital PE/Buyout Minority
Lighthouse Combined Investment Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Gencellmed FAQs

  • When was Gencellmed founded?

    Gencellmed was founded in 2019.

  • Where is Gencellmed headquartered?

    Gencellmed is headquartered in Seoul, South Korea.

  • What is the size of Gencellmed?

    Gencellmed has 9 total employees.

  • What industry is Gencellmed in?

    Gencellmed’s primary industry is Drug Discovery.

  • Is Gencellmed a private or public company?

    Gencellmed is a Private company.

  • What is Gencellmed’s current revenue?

    The current revenue for Gencellmed is .

  • How much funding has Gencellmed raised over time?

    Gencellmed has raised $5.81M.

  • Who are Gencellmed’s investors?

    Korean Venture Capital Association, DAYLI Partners, Innopolis Partners, KDB Capital, and Lighthouse Combined Investment are 5 of 9 investors who have invested in Gencellmed.

  • Who are Gencellmed’s competitors?

    Amgen and Daiichi Sankyo are competitors of Gencellmed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process